ArticleTransboundary and emerging diseases2025
European Preparedness for Japanese Encephalitis Virus Through Alignment of Animal Health Laboratory Diagnosis.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Outbreaks of Japanese encephalitis (JE) can have severe health and economic impacts in both humans and susceptible animal species and are estimated to cause ~68,000 human disease cases in Asia annually. The disease is caused by infection with the mosquito-borne JE virus (JEV), which continues to expand its geographical range from its endemic region in Asia. Since appropriate vertebrate host and mosquito vector species are present in Europe and average European summer temperatures continue to increase, JEV introduction could lead to the establishment of the pathogen in native mosquito species and wild birds and disease outbreaks among humans, pigs, and horses. Incursions could occur through movements of infected pigs and mosquitoes but also via migratory birds that act as reservoirs. Introduction and establishment of JEV in these populations may not be apparent at first, providing time for virus spread before spillover to the human population. Further complicating serological detection of JEV is the extensive cross-reactivity with other orthoflaviviruses circulating in Europe (i.e., tick-borne encephalitis virus [TBEV], West Nile virus [WNV], and Usutu virus [USUV]). In addition, viremia in clinical cases may be short, hindering virus detection. To facilitate European preparedness for detection, surveillance, and monitoring of JEV introduction and spread, five veterinary national reference laboratories in Europe collaborated with the aim to align JEV diagnostic pipelines to prepare for future emergence of JEV in Europe. All institutes assessed established and newly developed serological and molecular assays to build capability with sensitive and specific diagnostic tools for JEV detection. Additionally, methods for whole-genome sequencing (WGS) were established and compared. In summary, this project provides a framework for communication and international collaboration between arboviral researchers at national veterinary institutes. The sharing of knowledge and expertise, and alignment of diagnostic techniques, has facilitated improvement of diagnostic pipelines for JEV detection and contributed to preparedness for JEV introduction into Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.